Fluxion Biosciences, Inc. announced a new capability to include full-service clinical sample procurement that will expand Fluxion’s IsoFlux Discovery Services offering. Fluxion currently offers a broad range of analytical services using its IsoFlux System for circulating tumor cell (CTC) enrichment, including qPCR and next-generation sequencing (NGS) based assays. With this new capability, Fluxion can now provide clinical sample procurement that includes fresh blood draws from a wide range of cancer indications and tumor subtype profiles, such as Her2+, KRAS+, and EGFR+ samples.
Fluxion’s Discovery Services are available to biopharmaceutical, diagnostic, and research institutes that wish to conduct CTC studies on a contract basis. These services are provided out of Fluxion’s South San Francisco reference laboratory and utilize the cutting-edge IsoFlux technology as well as the circulating tumor cell experience of Fluxion’s scientific personnel. With this new offering, clients can now specify the number and types of clinical samples they wish to analyze and have them included in the study without having to set up any clinical agreements. The clinical samples are shipped overnight to Fluxion’s laboratory and processed the day of arrival. Each sample is highly annotated with clinical information and obtained under IRB consent.
“After running our Discovery Services for some time now, we realized that obtaining prospective clinical samples for CTC studies is a major bottleneck for our clients. Setting up clinical agreements, obtaining IRB approval, and waiting for patient recruitment can slow things down considerably,” said Mike Schwartz, Program Director at Fluxion. “This new addition to our service offering will dramatically increase the speed of discovery for our clients, not to mention make it easier to source an entire study from a single vendor.”